Dexcom (NYSE:DXCM) shares are up more than 9% today — a day after the company announced it will soon formally seek FDA clearance for its next-gen G7 system.
The San Diego-based diabetes management technology developer yesterday evening posted profits of $70.9 million, or 71¢ per share, on sales of $650.2 million for the three months ended Sept. 30, 2021, for a 1.8% bottom-line slide on sales growth of 29.8%.
Adjusted to exclude one-time items, earnings per share were 89¢, 26¢ ahead of Wall Street, where analysts were looking for sales of $617.8 million.
Get the full story at our sister site, Drug Delivery Business News.
This story originally ran on October 28, 2021. Updated October 29 with stock price and news from earnings call.